

Clean version of amended claims

F.  
E1

1. (twice amended) A method for preparing a stable, retroviral packaging cell line for generation of human serum-resistant retroviral particles (RVP) which comprises

(a) introducing one or more packaging vectors into a non-primate mammalian cell line, wherein said cell line exhibits no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe and is capable of producing human serum-resistant RVP and wherein said vectors, either singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and

(b) recovering said packaging cell line;

with the proviso that the non-primate mammalian cell line is not BHK.

E2

3. (twice amended) The method of Claim 1, wherein said cell line is human serum-resistant.

E3

20. (amended) Retroviral vector particles produced by the methods of any one of Claims 11, 16, 44 or 45. F

E4  
F2

46. (amended) A method for preparing a stable, retroviral packaging cell line for generation of human serum-resistant retroviral particles (RVP) which comprises

(a) introducing one or more packaging vectors into a human serum-resistant non-primate mammalian cell line wherein said vectors, either singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and

(b) recovering said packaging cell line.

E5

48. (amended) The method of Claim 46, wherein said cell line exhibits no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe.

50. (amended) A packaging cell line produced by the method of Claim 46 or 47.

51. (amended) A method for preparing stable, retroviral producer cells capable of producing human serum-resistant retroviral vector particles (RVP) which comprises

E6

(a) introducing a retrovirus vector into the packaging cell line of Claim 46, wherein said retrovirus vector is capable of being packaged into an RVP and comprises a heterologous gene capable of expression in a human; and

(b) recovering said producer cells.

E7

53. (amended) The method of Claim 51, wherein said cells exhibit no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe.

E8

58. (amended) The method of Claim 56 wherein said cell line exhibits no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe.

E9

63. (amended) The method of Claim 61, wherein said cells exhibit no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe.